3
Announcements
Trials
Browse
Landscape
Status
Recruiting
179
Active not recruiting
92
Completed
34
Not yet recruiting
32
Terminated
24
Suspended
7
Withdrawn
3
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Amyloidosis
1
Interventions
balstilimab
2
3-Iodobenzylguanidine
2
zolbetuximab
1
zipalertinib
1
venetoclax
1
ulixertinib
1
tisagenlecleucel
1
tipifarnib
1
talazoparib
1
selinexor
1
ruxolitinib
1
ribociclib
1
nirogacestat
1
mirdametinib
1
mifamurtide
1
lifileucel
1
leronlimab
1
idecabtagene vicleucel
1
fluorodopa F 18
1
fluorocholine
1
dodecyl maltoside
1
carbon-11 methionine
1
brexucabtagene autoleucel
1
axicabtagene ciloleucel
1
asciminib
1
Sunitinib
1
Proton Pump Inhibitors
1
Peripheral Blood Stem Cell Transplantation
1
Methionine
1
Magnetic Resonance Spectroscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Available
×
venetoclax
×
1 year
×
Clear all
NCT03123029
2026-01-30
Expanded Access to Venetoclax
AbbVie
Available